Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1166900

registered interest
date	28/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to fulfill its commitment in its Prevention Green Paper to seek views on how to improve the healthy social and emotional development of babies and young children.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	6261
answer	answer is ministerial correction date of answer 05/11/2019 answer text <p>The Government is taking steps to fulfil its commitment in its Prevention Green Paper to seek views on how to improve the healthy social and emotional development of babies and young children.</p><p>Public Health England’s (PHE’s) vision is to improve the health of babies, children and their families and to enable the foundations of good health into adulthood. A large proportion of this work will be done through the modernisation of the Healthy Child Programme, which is PHE’s national offer to our children and families. This can be viewed at the following links:</p><p> </p><p><a href="https://www.gov.uk/government/publications/healthy-child-programme-pregnancy-and-the-first-5-years-of-life" target="_blank">https://www.gov.uk/government/publications/healthy-child-programme-pregnancy-and-the-first-5-years-of-life</a></p><p><a href="https://www.gov.uk/government/publications/healthy-child-programme-5-to-19-years-old" target="_blank">https://www.gov.uk/government/publications/healthy-child-programme-5-to-19-years-old</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 05/11/2019 12:02:19 answering member 4380 label Biography information for Jo Churchill
tabling member	1439 label Biography information for Norman Lamb

1150324

registered interest
date	17/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Disability
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the risks posed to people living with disabilities by a lack of availability of (a) medicines and (b) essential medical equipment in the event of the UK leaving the EU without a withdrawal agreement.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	1607
answer	answer is ministerial correction date of answer 22/10/2019 answer text <p>The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products once we have left the EU.</p><p>The Department, as part of our EU exit preparations, has analysed the supply chains of over 12,000 licensed medicines used by patients in the United Kingdom and close to half a million product lines of medical devices and clinical consumables with an EU/European Economic Area touchpoint. This approach means that the medicines and medical equipment used by people living with disabilities are included within our planning.</p><p>We continue to implement a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:</p><p><a href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans" target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a>.</p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 22/10/2019 15:31:09 answering member 4362 label Biography information for Edward Argar
tabling member	1439 label Biography information for Norman Lamb

1149333

registered interest
date	15/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Epilepsy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether anti-epileptic drugs are exempted from serious shortage protocols; and what assessment he has made of the potential effect of the use of such protocols on (a) people with learning disabilities and (b) their families in the event that the UK leaves the EU without a withdrawal agreement.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	475
answer	answer is ministerial correction date of answer 21/10/2019 answer text <p>While Serious Shortage Protocols (SSP) in England have the scope to cover all medicines and appliances that are on a National Health Service prescription in primary care, including anti-epileptic drugs, it is clear that an SSP for therapeutic or generic equivalents will not necessarily be suitable for all medicines and patients. For example, where medicines need to be prescribed by brand for clinical reasons, which is the case for epilepsy medication.</p><p>Any protocol would only be introduced if clinicians with expertise in the relevant area think it is appropriate. Pharmacists will have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate or the patient should be referred to their prescriber.</p><p>The legislation enabling Ministers to issue SSPs was not introduced as a European Union exit measure alone but as a business-as-usual measure that can be used before and after our exit from the EU.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 21/10/2019 13:07:33 answering member 4362 label Biography information for Edward Argar
tabling member	1439 label Biography information for Norman Lamb

1149339

registered interest
date	15/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Epilepsy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of the availability of anti-epilepsy medications in the event that the UK leaves the EU without a deal.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	479
answer	answer is ministerial correction date of answer 21/10/2019 answer text <p>The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products, including those used for the treatment of epilepsy, once we have left the EU.</p><p>The Department, as part of our EU exit preparations, is implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:</p><p><a href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans" target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a></p><p>We have been working closely with suppliers to monitor over 300 different epilepsy medicines provided by almost 50 companies and we are pleased to see many are holding stockpiles far beyond the six weeks’ additional buffer we requested. We also know that the vast majority of those suppliers with lower levels of stockpiles are taking action to re-route their supply chains away from the short straits crossings where applicable.</p><p> </p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 21/10/2019 13:04:06 answering member 4362 label Biography information for Edward Argar
tabling member	1439 label Biography information for Norman Lamb

1147165

registered interest
date	30/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Chief Scientific Advisers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many meetings he had with his Department’s Chief Scientific Adviser from 1 June to 31 August 2019.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	292148
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>For the period 1 June 2019 to 31 August 2019 my Rt. Hon. Friend the Secretary of State for Health and Social Care met with the Department’s Chief Scientific Adviser (CSA) three times, the CSA met with other Health Ministers on seven occasions.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 08/10/2019 10:30:10 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1439 label Biography information for Norman Lamb

1143605

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) raise awareness of and (b) increase access to the PrEP impact trial in BAME communities.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	285065
answer	answer is ministerial correction date of answer 05/09/2019 answer text <p>A core function of the pre-exposure prophylaxis (PrEP) Impact Trial Community Advisory Board (CAB) is to raise awareness and uptake of PrEP in key populations including women and black, Asian and minority ethnic (BAME) communities. Further information about PrEP Impact Trial CAB activities and participating community groups can be found at the following links:</p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/</a></p><p><a href="https://www.prepimpacttrial.org.uk/faqs" target="_blank">https://www.prepimpacttrial.org.uk/faqs</a></p><p>In addition, Public Health England’s Innovation Fund has supported a number of community based projects aimed at increasing PrEP awareness in women, BAME groups and trans communities; information on the projects funded in 2018 can be found at the following links:</p><p><a href="https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018" target="_blank">https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018</a></p><p>Since the start of the PrEP Impact Trial in October 2017, over half of the available 26,000 trial places have been filled. As of 3 September 2019, all participating Trial clinics were open to recruitment for women, trans men and heterosexual men. Information on the enrolment status of participating clinics is regularly updated on the PrEP Impact Trial website at the following link:</p><p><a href="https://www.prepimpacttrial.org.uk/join-the-trial" target="_blank">https://www.prepimpacttrial.org.uk/join-the-trial</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 285069 question first answered 05/09/2019 15:28:31 answering member 4380 label Biography information for Jo Churchill
tabling member	1439 label Biography information for Norman Lamb

1143606

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) raise awareness of and (b) increase access to the PrEP impact trial amongst women at high risk of contracting HIV.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	285069
answer	answer is ministerial correction date of answer 05/09/2019 answer text <p>A core function of the pre-exposure prophylaxis (PrEP) Impact Trial Community Advisory Board (CAB) is to raise awareness and uptake of PrEP in key populations including women and black, Asian and minority ethnic (BAME) communities. Further information about PrEP Impact Trial CAB activities and participating community groups can be found at the following links:</p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/</a></p><p><a href="https://www.prepimpacttrial.org.uk/faqs" target="_blank">https://www.prepimpacttrial.org.uk/faqs</a></p><p>In addition, Public Health England’s Innovation Fund has supported a number of community based projects aimed at increasing PrEP awareness in women, BAME groups and trans communities; information on the projects funded in 2018 can be found at the following links:</p><p><a href="https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018" target="_blank">https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018</a></p><p>Since the start of the PrEP Impact Trial in October 2017, over half of the available 26,000 trial places have been filled. As of 3 September 2019, all participating Trial clinics were open to recruitment for women, trans men and heterosexual men. Information on the enrolment status of participating clinics is regularly updated on the PrEP Impact Trial website at the following link:</p><p><a href="https://www.prepimpacttrial.org.uk/join-the-trial" target="_blank">https://www.prepimpacttrial.org.uk/join-the-trial</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 285065 question first answered 05/09/2019 15:28:31 answering member 4380 label Biography information for Jo Churchill
tabling member	1439 label Biography information for Norman Lamb

1140582

registered interest
date	19/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to issue guidance to health professionals on the Serious Shortage Protocol.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	279389
answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:34:54 answering member 4455 label Biography information for Seema Kennedy previous answer version 131086 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
tabling member	1439 label Biography information for Norman Lamb

1140584

registered interest
date	19/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans the Government has provide information to patients on changes to the provision of medicines as a result of the serious shortage protocol; and if he will make a statement.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	279390
answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279391 question first answered 26/07/2019 11:36:12 answering member 4455 label Biography information for Seema Kennedy previous answer version 131087 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
tabling member	1439 label Biography information for Norman Lamb

1140585

registered interest
date	19/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions the Government has had with (a) patient groups and (b) professional bodies on the development of the serious shortage protocol.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	279391
answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279390 question first answered 26/07/2019 11:36:13 answering member 4455 label Biography information for Seema Kennedy previous answer version 131085 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
tabling member	1439 label Biography information for Norman Lamb